The level of telomere dysfunction determines the efficacy of telomerase-based therapeutics in a lung cancer cell line.

International journal of oncology

Volumn 26, Issue 5, 2005, Pages 1227-1232

  Pantic, Milena ^a   Zimmermann, Stefan ^a   Waller, Cornelius F ^a   Martens, Uwe M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; TELOMERASE;

ARTICLE; CELL CULTURE; CELL SURVIVAL; DRUG ANTAGONISM; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; TELOMERE; ULTRASTRUCTURE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; DNA-BINDING PROTEINS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; TELOMERASE; TELOMERE; TUMOR CELLS, CULTURED;

MLCS; MLOWN;

EID: 21444438871     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.26.5.1227     Document Type: Article

References (0)